Phase Ia/Ib Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: 
Safety, Efficacy, and Biomarkers
Yakun Wang(Peking University), Lin Shen(Peking University), Yunpeng Liu(Capital Medical University), Jinghong Zhou, Yuxian Bai(Harbin Medical University), Wei Li(Jilin University), Tao� Zhang(Ningbo University), Li Liu(Shihezi University), Li Zhang(Peking University), Tianshu Liu(Sun Yat-sen University), Jianming Xu(Chinese PLA General Hospital), Jianxing He(First Affiliated Hospital of Guangzhou Medical University), Jian Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Liya Zhang(Sun Yat-sen University), Mengzhao Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Da Jiang(Hebei Medical University), Nong Xu(Zhejiang University), Gongyan Chen(Harbin Medical University), Jianhua Chang(Shanghai Medical College of Fudan University), Weiguo Su(Tamedia (Switzerland)), Jifang Gong(Peking University), Chunmei Bai(Shanxi Medical University), Baorui Liu(Nanjing Drum Tower Hospital), Yongxin Ren
Cited by 15
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k